AB Science (OTCMKTS:ABSCF) Shares Up 7.9% – Should You Buy?

AB Science S.A. (OTCMKTS:ABSCF)’s stock price shot up 7.9% on Wednesday . The stock traded as high as $1.37 and last traded at $1.37. 863 shares changed hands during mid-day trading, an increase of 73% from the average session volume of 500 shares. The stock had previously closed at $1.27.

AB Science Stock Up 7.9%

The company’s fifty day moving average is $1.45 and its two-hundred day moving average is $1.36.

AB Science Company Profile

AB Science is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the discovery and development of protein kinase inhibitors. Its core focus is on the design of orally administered small-molecule therapies that target key signaling pathways involved in oncology, inflammatory disorders and neurodegenerative diseases. The company’s lead asset, masitinib, is a selective tyrosine kinase inhibitor that has been evaluated in multiple Phase 2 and Phase 3 clinical trials, including studies in mastocytosis, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and severe asthma.

Since its founding in 2001 by Dr.